Skip to main
TRAW

Traws Pharma (TRAW) Stock Forecast & Price Target

Traws Pharma (TRAW) Analyst Ratings

Based on 1 analyst ratings
Hold
Strong Buy 0%
Buy 0%
Hold 100%
Sell 0%
Strong Sell 0%

Bulls say

Traws Pharma is currently going through regulatory hurdles and studies to potentially restart the TXM program, which could provide a major de-risking event for investors. Despite the potential for setbacks with the FDA's clinical hold, management is actively working to resolve the issues and the company is also pursuing an alternate path for generating human proof-of-concept data through a U.K. challenge study. Additionally, Traws Pharma's plans to reposition TXM as a once-monthly prophylactic agent for seasonal influenza prevention expands its commercial potential and adds to the company's overall value.

Bears say

Traws Pharma is a clinical-stage biopharmaceutical company with four clinical programs focusing on developing antiviral agents. However, the company's negative outlook is driven by concerns over its funding solution beyond 1Q27, as well as various risks such as financing, clinical trial, regulatory, delisting, and bankruptcy. These concerns outweigh the potential upside from pipeline success and a potential large market for COVID, hantavirus, or Ebola. Overall, the company may face challenges in achieving profitability in the near future.

Traws Pharma (TRAW) has been analyzed by 1 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 0% recommend Buy, 100% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Traws Pharma and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Traws Pharma (TRAW) Forecast

Analysts have given Traws Pharma (TRAW) a Hold based on their latest research and market trends.

According to 1 analysts, Traws Pharma (TRAW) has a Hold consensus rating as of Sep 10, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Traws Pharma (TRAW)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.